Capricor Gets Second FDA Rejection for Muscular Dystrophy Drug, Bloomberg reports
Capricor Therapeutics Inc. received a second FDA rejection for its muscular dystrophy drug, Bloomberg reports.
How this was made
The 30-second read
Why it matters
A second FDA rejection is a major regulatory milestone that typically forces biotech to reassess development strategy, timelines, and capital needs.
Market read
Regulatory denial risk is likely to dominate CAPR’s near-term trading as investors reprice the program’s prospects.
What to watch
The article provides no details on the rejection rationale, whether it was for CMC, trial design, endpoints, or safety, which can materially change the probability of a successful next attempt.
Background
The piece reports that Capricor’s muscular dystrophy therapy has been rejected by US regulators for the second time.
Ticker impact
Capricor Therapeutics’ muscular dystrophy therapy was rejected for the second time by US regulators, a direct regulatory setback for CAPR.
Likely downward pressure as traders price in higher regulatory risk and potential need for redesign, additional trials, or revised endpoints.
The article states a second FDA rejection, which is a material, company-specific regulatory outcome that typically worsens risk perception and financing optionality for biotech programs.
Market effects
Adds to negative read-through on FDA review risk for rare-disease muscular dystrophy therapies and similar clinical-stage programs.
Primarily US biotech sentiment, with potential spillover to other small-cap rare-disease names.
Limited direct global impact, but can affect international investor sentiment toward US regulatory outcomes in rare disease.
Counterpoint
A second rejection can still leave room for resubmission if the FDA cited specific deficiencies that are addressable, limiting permanent impairment.
Key entities
- companyCapricor Therapeutics Inc.
US biotech developing a therapy for a deadly form of muscular dystrophy, facing a second FDA rejection.



